Longitudinal evidence on the association between interleukin-6 and C-reactive protein with the loss of total appendicular skeletal muscle in free-living older men and women
- PMID: 21565862
- DOI: 10.1093/ageing/afr040
Longitudinal evidence on the association between interleukin-6 and C-reactive protein with the loss of total appendicular skeletal muscle in free-living older men and women
Abstract
Background: there is no longitudinal evidence about the association between the loss of total appendicular skeletal muscle (TASM) and cytokines.
Objective: to investigate whether high levels of the inflammatory markers such as interleukin-6 (IL-6) and C-reactive protein (CRP) are associated with the loss of TASM in free-living non-sarcopenic older people.
Design: five-year prospective cohort study.
Subjects: one hundred and fifteen free-living non-sarcopenic older men and women aged 60-84 years at baseline and 5-year follow-up were included.
Methods: TASM was measured by dual-energy X-ray absorptiometry, and the relative change in TASM was calculated. The response variable was the loss of TASM defined as the lowest sex-specific 15th percentile of the cohort distribution of percentage of change in TASM. The exposure variables were the baseline serum IL-6 and CRP levels measured by ELISA.
Results: sixteen subjects were below the sex-specific 15th percentile of the cohort. The mean absolute loss of TASM in these men and women subjects was 1.9 and 1.3 kg, respectively. The risk of loss TASM was 1.29 times higher (95% confidence interval [CI], 1.01-1.64) (P = 0.03) per unit of increase in IL-6 (pg/ml) and 1.28 times higher (95% CI, 1.04-1.58) (P = 0.01) per unit of increase in CRP (mg/l). As a categorical variable, the risk of loss TASM was 4.85 times higher (95% CI, 1.24-18.97) among subjects with serum IL-6 >2.71 pg/ml and 3.97 times higher (CI 95%, 1.09-14.39) among subjects with serum CRP >3.74 mg/l. These findings remained after adjusting for age, sex and 5-year weight change.
Conclusions: inflammation is associated with the loss of TASM in free-living non-sarcopenic older men and women.
Similar articles
-
Inflammatory markers and loss of muscle mass (sarcopenia) and strength.Am J Med. 2006 Jun;119(6):526.e9-17. doi: 10.1016/j.amjmed.2005.10.049. Am J Med. 2006. PMID: 16750969
-
Association between insulin resistance and low relative appendicular skeletal muscle mass: evidence from a cohort study in community-dwelling older men and women participants.J Gerontol A Biol Sci Med Sci. 2014 Jul;69(7):871-7. doi: 10.1093/gerona/glt193. Epub 2013 Dec 10. J Gerontol A Biol Sci Med Sci. 2014. PMID: 24325896
-
Hyperinsulinemia is associated with the loss of appendicular skeletal muscle mass at 4.6 year follow-up in older men and women.Clin Nutr. 2015 Oct;34(5):931-6. doi: 10.1016/j.clnu.2014.09.022. Epub 2014 Oct 7. Clin Nutr. 2015. PMID: 25453394
-
Inflammatory markers and cortisol parameters across depressive subtypes in an older cohort.J Affect Disord. 2018 Jul;234:54-58. doi: 10.1016/j.jad.2018.02.080. Epub 2018 Feb 27. J Affect Disord. 2018. PMID: 29522944 Review.
-
Inflammation and sarcopenia: A systematic review and meta-analysis.Maturitas. 2017 Feb;96:10-15. doi: 10.1016/j.maturitas.2016.11.006. Epub 2016 Nov 13. Maturitas. 2017. PMID: 28041587 Review.
Cited by
-
5'-Cytimidine Monophosphate Ameliorates H2O2-Induced Muscular Atrophy in C2C12 Myotubes by Activating IRS-1/Akt/S6K Pathway.Antioxidants (Basel). 2024 Feb 19;13(2):249. doi: 10.3390/antiox13020249. Antioxidants (Basel). 2024. PMID: 38397848 Free PMC article.
-
Pathogenesis and comprehensive treatment strategies of sarcopenia in elderly patients with type 2 diabetes mellitus.Front Endocrinol (Lausanne). 2024 Jan 8;14:1263650. doi: 10.3389/fendo.2023.1263650. eCollection 2023. Front Endocrinol (Lausanne). 2024. PMID: 38260146 Free PMC article. Review.
-
Energy Regulation in Inflammatory Sarcopenia by the Purinergic System.Int J Mol Sci. 2023 Nov 29;24(23):16904. doi: 10.3390/ijms242316904. Int J Mol Sci. 2023. PMID: 38069224 Free PMC article. Review.
-
A comprehensive review on the risks assessment and treatment options for Sarcopenia in people with diabetes.J Diabetes Metab Disord. 2023 Jul 30;22(2):995-1010. doi: 10.1007/s40200-023-01262-w. eCollection 2023 Dec. J Diabetes Metab Disord. 2023. PMID: 37975099 Review.
-
Sarcopenia and COVID-19 Outcomes.Clin Interv Aging. 2023 Mar 9;18:359-373. doi: 10.2147/CIA.S398386. eCollection 2023. Clin Interv Aging. 2023. PMID: 36923269 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
